LION bioscience Announces GlaxoSmithKline License Expansion
back to LION bioscience home
SitemapPrintable version of this documentContact LIONZur deutschen Version dieses Dokuments LION bioscience AG
Press
Press Releases
2004
2003
2002
2001
2000
1999
1998
1997
Ad-Hoc Releases
Online Press Kit
Events
Photos & Logos
Glossary
PR Contact
 

© 2004 LION bioscience AG
Disclaimer
Imprint/Contact
Contact Webmaster
LION bioscience Announces GlaxoSmithKline License Expansion
 

Cambridge, MA, USA, Heidelberg, Germany, April 7, 2004 – LION bioscience (Nasdaq: LEON) today announced that GlaxoSmithKline (GSK) has renewed its license for SRS and SRS Objects. With these renewals, which were received by the company in third quarter of fiscal year 2003/2004, GSK has expanded its collaboration with LION and has the license to use the LION technology globally. Financial details were not disclosed.

SRS is a proven, scalable and robust data integration platform that provides fast access to diverse life science data - genetic, protein, cellular, molecular and clinical - from public and proprietary sources, regardless of data format. SRS is used in more than 300 commercial and academic sites delivering genomic data daily to thousands of users around the globe. SRS is the clear market leader for bioinformatics data integration, providing global bioinformatics platforms for pharmaceutical companies such as Eli Lilly, Johnson&Johnson and AstraZeneca, as well as forming the basis of genomics portals for leading data providers such as Celera, Incyte, Derwent and Affymetrix.

“We are pleased that SRS continues to be the standard integration technology for biological data. With the release of SRS 8.0 this summer, we believe that this leading position will be further expanded,” said Dr. Daniel Keesman, co-CEO and Chief Operating Officer at LION.


For further information please contact:

Julia Fritz
Corporate Communications
+49 (0) 6221 4038 158
julia.fritz@lionbioscience.com

About LION bioscience

LION bioscience (ISIN: DE0005043509, Reuters: LIOG, Bloomberg: LIO, Nasdaq: LEON) provides proven information and knowledge management solutions to significantly improve life science R&D performance and productivity. Since it was founded in 1997, the company has become a recognized leader in the area of life sciences informatics. LION has operations worldwide with its headquarter in Heidelberg, Germany, and offices in Cambridge, UK, and Cambridge, MA, USA. LION’s products are distributed by CTC Systems in Japan and DigiGenomics in Taiwan and Korea.

LION’s (http://www.netgenics.com) solutions are used by more than 27,000 researchers at 300 academic and industrial customers globally. LION’s offerings include SRS for bioinformatics data access, LION Target Engine™ for target identification and validation, LION Lead Engine™ for lead identification and optimization, iDEA pkEXPRESSä with analysis and prediction tools for ADME, and LION SolutionCenter™ professional services.


###
Except for the historical information contained herein, the matters set forth in this press release are forward looking within the meaning of the Private Securities Litigation Reform Act of 1995, and other applicable U.S. and German laws. These forward-looking statements may include projections, estimates, targets, goals and descriptions of future events. Such statements are based on the current targets that LION has set itself and on LION’s current expectations, each of which is subject to risks and uncertainties. LION’s actual results may vary materially from those targeted, expected or projected because of factors such as uncertainties relating to technologies, product and solution development, acceptance by the market of LION’s offerings, market or industry trends, success of LION’s business model and strategy, competition, exchange rate fluctuations, cost or pricing of LION’s products and solutions, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, or patent or copyright protection and litigation. We refer you to LION’s Annual Reports on Form 20-F, as filed with the Securities and Exchange Commission (SEC), as well as LION’s SEC filing, as filed on September 30, 2003, in which these and other risk factors are discussed. LION expressly disclaims any obligation or undertaking to release publicly any updates, revisions or corrections to any forward-looking statements or historical information contained in this announcement, whether as a result of new information, change of assumptions or business model, future developments or otherwise. LION bioscience®, Life Science Informatics™, LION DiscoveryCenter™, LION SolutionCenter™, LION Hosted Services™, LION Target Engine™, LION Lead Engine™, LSI™, bioSCOUT®, arraySCOUT™, arrayTAG™, arrayBASE™, genomeSCOUT™, pathSCOUT™, pSCOUT™ and iDEA™ are either registered trademarks of LION bioscience AG or its subsidiaries in the United States and/or other countries, or there are pending applications by LION bioscience AG or its subsidiaries for these trademarks in the United States and/or other countries. The names of actual companies and products mentioned herein may be the trademark of the respective owners.
###

Download as Word Document
Download as PDF Document